{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:21:35Z","timestamp":1788153695113,"version":"build-2803163510"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Immunotherapy and targeted therapy have gained ground over conventional chemotherapy in treating various cancers. While pulmonary toxicity associated with these agents is rare, it represents a significant factor in both mortality and morbidity and may influence the overall success of cancer treatment. This case series report adds to the emerging evidence of cancer therapy-induced pneumonitis features and corticotherapy outcomes. Patients and methods: This single-center, retrospective case series analyzed 12 consecutive cases of patients undergoing immunotherapy (four receiving nivolumab, four receiving pembrolizumab) or targeted therapy (three receiving obinutuzumab, one receiving abemaciclib) for cancer (seven with lung cancer, three with non-Hodgkin lymphoma, one with breast cancer, one with renal cancer) who developed pneumonitis during their follow-up. Results: The interval from oncological treatment initiation to pneumonitis onset ranged from 6 to 48 months (median = 18.5), and in four patients it occurred after discontinuation of oncologic therapy. In most patients, the diagnosis was established with high probability based only on the clinical presentation, radiologic pattern, and concomitant oncologic therapy. Bronchoscopy with bronchoalveolar lavage analysis was performed in eight of the 12 patients, particularly when onset followed treatment discontinuation. The main symptom was dyspnea (10\/12 cases), and three of 12 patients had respiratory failure (SpO2 \u2264 88%). The CTCAE severity grades were: one mild, seven moderate, three severe, and one life-threatening. The CT scan showed different patterns (7 OP, 4 NSIP-like, and 1 HP). Eleven patients received oral methylprednisolone (0.40 to 0.82 mg\/kg) for 5 to 16 weeks. Two patients continued oncologic treatment, and six discontinued. Pneumonitis improved or resolved in 11 of the 12 patients; one patient deteriorated after reintroduction of immunotherapy and subsequently died from cancer-related complications. Conclusions: Immunotherapy- and targeted therapy-induced pneumonitis can express various features and severities, and prompt recognition and diagnosis based on clinical, radiologic and contextual elements are mandatory. In this small, heterogeneous series the individualized corticosteroid regimens used were followed by favorable outcomes. Our observations suggest that, in selected clinically improving patients, follow-up may rely only on clinical assessment and chest X-ray, and extensive tests may be reserved for non-responsive cases.<\/jats:p>","DOI":"10.3390\/diseases14090313","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:26:03Z","timestamp":1787837163000},"page":"313","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pneumonitis Associated with Immune Checkpoint Inhibitors and Targeted Anticancer Therapies: A Retrospective Case Series of 12 Patients"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0596-2122","authenticated-orcid":false,"given":"Claudia Lucia","family":"Toma","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Pneumology IV Department, Marius Nasta Institute of Pulmonology, 050159 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8204-7173","authenticated-orcid":false,"given":"\u0218tefania Florina","family":"Oprea","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Pneumology IV Department, Marius Nasta Institute of Pulmonology, 050159 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0292-2453","authenticated-orcid":false,"given":"\u0218tefan","family":"Dumitrache-Rujinski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Pneumology IV Department, Marius Nasta Institute of Pulmonology, 050159 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Ionela Nicoleta","family":"Belaconi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Pneumology IV Department, Marius Nasta Institute of Pulmonology, 050159 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Daniela","family":"Jipa-Dun\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Pneumology IV Department, Marius Nasta Institute of Pulmonology, 050159 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9933-8965","authenticated-orcid":false,"given":"Cristian","family":"Cojocaru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"Alexandra Maria","family":"Cristea","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Pneumology IV Department, Marius Nasta Institute of Pulmonology, 050159 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-260X","authenticated-orcid":false,"given":"Camelia Cristina","family":"Diaconu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Internal Medicine Department, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-6862","authenticated-orcid":false,"given":"Dragos Cosmin","family":"Zaharia","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Pneumology IV Department, Marius Nasta Institute of Pulmonology, 050159 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1158\/1535-7163.MCT-17-0155","article-title":"Risk of pneumonitis associated with programmed cell death 1 inhibitors in cancer patients: A meta-analysis","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e004670","DOI":"10.1136\/jitc-2022-004670","article-title":"Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: A multi-institutional cohort study","volume":"10","author":"Tiu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of Pneumonitis with Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e001170","DOI":"10.1136\/jitc-2020-001170","article-title":"Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: A network meta-analysis","volume":"8","author":"Chen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3109\/10428194.2014.963075","article-title":"Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab","volume":"56","author":"Salmasi","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1080\/10428190802270886","article-title":"Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma","volume":"49","author":"Liu","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Saunders, S., and Fryman, C. (2024, January 17\u201322). An Original Occurrence of Organizing Pneumonia from Obinutuzumab. Proceedings of the American Thoracic Society International Conference Meetings Abstracts, San Diego, CA, USA.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A3854"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e70258","DOI":"10.1002\/rcr2.70258","article-title":"Organising Pneumonia in a Patient Following Obinutuzumab for Follicular Lymphoma","volume":"13","author":"Nanda","year":"2025","journal-title":"Respirol. Case Rep."},{"key":"ref_12","unstructured":"FDA (2025, June 30). FDA Warns About Rare but Severe Lung Inflammation with Ibrance, Kisqali, and Verzenio for Breast Cancer, Available online: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/ibrance-palbociclib-kisqali-ribociclib-and-verzenio-abemaciclib-drug-safety-communication-due-rare."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.21037\/tlcr-20-582","article-title":"Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: A case series","volume":"10","author":"Kimura","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1148\/radiology.179.1.2006262","article-title":"Chronic diffuse interstitial lung disease: Diagnostic value of chest radiography and high-resolution CT","volume":"179","author":"Grenier","year":"1991","journal-title":"Radiology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Shannon, V.R. (2019). Cancer treatment-related lung injury. Oncologic Critical Care, Springer.","DOI":"10.1007\/978-3-319-74698-2_52-1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1148\/rg.2019190036","article-title":"Immune checkpoint inhibitor therapy\u2013related pneumonitis: Patterns and management","volume":"39","author":"Kalisz","year":"2019","journal-title":"RadioGraphics"},{"key":"ref_17","unstructured":"(2025, June 30). Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Available online: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/CCO.0000000000000736","article-title":"Supportive care for new cancer therapies","volume":"33","author":"Rapoport","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mir, M., Soto, F., Gomez, P.A.A., Arroyo, R.D.R., Suresh, A., Su, A., Gan, Q., Stewart, J., Adachi, R., and Balachandran, D.D. (2025). Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitis. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1646108"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-020-02650-z","article-title":"Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma","volume":"18","author":"Strippoli","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+\/HER2\u2212 Metastatic Breast Cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2214\/AJR.21.25454","article-title":"Imaging of Oncologic Treatment\u2013Related Pneumonitis: A Focused Review on Emerging Issues of Immune Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation","volume":"218","author":"Nishino","year":"2022","journal-title":"Am. J. Roentgenol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 Inhibitor\u2013Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"\u0130lhan, N., Do\u011fan, A., Er\u00f6lmez, H.N., Atalah, F., Ba\u015f, S., Yasar, S., Odaba\u015f, H., and G\u00fcm\u00fc\u015f, M. (2025). The Incidence and Clinical Characteristics of Interstitial Lung Disease Associated with CDK4\/6 Inhibitors in Breast Cancer Patients: A Retrospective Multicenter Study. Medicina, 61.","DOI":"10.3390\/medicina61030549"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Huang, A., Xu, Y., Zang, X., Wu, C., Gao, J., Sun, X., Xie, M., Ma, X., Deng, H., and Song, J. (2021). Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08353-y"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Huang, H., Chen, R., Xu, Y., Fang, N., Shao, C., Xu, K., and Wang, M. (2024). The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010255"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100126","DOI":"10.1016\/j.chstcc.2024.100126","article-title":"Managing Immune Checkpoint Inhibitor Pneumonitis in the ICU","volume":"3","author":"Montemayor","year":"2025","journal-title":"CHEST Crit. Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e000840","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune checkpoint inhibitor pneumonitis","volume":"8","author":"Naidoo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.21037\/tlcr-22-732","article-title":"Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: A retrospective multi-center cohort study","volume":"11","author":"Lin","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pccm.2024.12.001","article-title":"Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions","volume":"3","author":"Xu","year":"2025","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s12282-020-01207-8","article-title":"Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan","volume":"28","author":"Chen","year":"2021","journal-title":"Breast Cancer"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/9\/313\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:59:32Z","timestamp":1788152372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/9\/313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["diseases14090313"],"URL":"https:\/\/doi.org\/10.3390\/diseases14090313","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}